A password will be e-mailed to you.

Some investors might be leery of Aurora Cannabis (NYSE:ACB) right now — even those who cheered for the stock earlier this year. You can count Bank of America Merrill Lynch analyst Christopher Carey in that group. After recommending Aurora in April, Carey reversed course earlier this month and downgraded the stock to a neutral rating. I suspect that most investors who are skittish about Aurora are, like Carey, focusing on the short-term challenges the company faces. My view is that these short-term issues aren’t anything to be too concerned about. However, one thing about Aurora Cannabis is worrisome to me. Aurora Cannabis’ Big, Scary Number That Should Make Investors Nervous

thumbnail courtesy of fool.com